New Phase 3 STELARA® (ustekinumab) Data Show Positive Results As Maintenance Therapy In Adults With Moderate To Severe Ulcerative Colitis

New Phase 3 STELARA® (ustekinumab) Data Show Positive Results As Maintenance Therapy In Adults With Moderate To Severe Ulcerative Colitis

Amgen, Entera to Partner on Oral Drugs for Inflammatory Disease, Other “Serious” Illnesses

Amgen, Entera to Partner on Oral Drugs for Inflammatory Disease, Other “Serious” Illnesses

FDA Approves Humira Biosimilar That Won’t Be Available Until 2023

FDA Approves Humira Biosimilar That Won’t Be Available Until 2023

Έγκριση του tofacitinib citrate στην Ευρώπη για την ελκώδη κολίτιδα

Έγκριση του tofacitinib citrate στην Ευρώπη για την ελκώδη κολίτιδα

MSD’s ulcerative colitis drug scores expanded indication in Europe

  New Jersey-based multinational MSD have announced that the European Commission (EC) has approved Simponi (golimumab) for early dose optimisation in ulcerative colitis (UC) for patients with body weight less than 80kg who do not respond adequately to induction therapy. The approval follows a positive opinion issued by the Committee for Medicinal Products for Human … Συνεχίστε να διαβάζετε MSD’s ulcerative colitis drug scores expanded indication in Europe.